Xiaochuan Huo1, Anxin Wang2,3,4, Dapeng Mo1, Feng Gao1, Ning Ma1, Yilong Wang2,3,4, Yongjun Wang2,3,4, Zhongrong Miao1. 1. Neurointervention Center, Beijing Tiantan Hospital, Capital Medical University, Beijing, China. 2. Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China. 3. China National Clinical Research Center for Neurological Diseases, Beijing, China. 4. Center of Stroke, Beijing Institute for Brain Disorders, Beijing, China.
Abstract
Objective: To investigate the safety and efficacy of tirofiban in acute ischemic stroke (AIS) patients with large artery atherosclerosis (LAA) stroke etiology receiving endovascular therapy (EVT). Methods: In this multi-center prospective study, patients who were considered to have an indication received a low dose intra-arterial bolus (0.25-1 mg) of tirofiban. The safety and efficacy outcomes at 90-day follow-ups included symptomatic intracranial hemorrhage (sICH), recanalization rate, functional outcome, and mortality. Results: Among the 649 AIS patients with LAA, those in the tirofiban group (n = 244) showed higher systolic blood pressure (BP) and NIHSS score on admission, puncture-to-recanalization time, lower frequency of intravenous thrombolysis and intra-arterial thrombolysis, higher frequency of antiplatelet, heparinization, mechanical stent retrieval, aspiration, balloon angioplasty, and more retrieval times compared with those in the non-tirofiban group (n = 405) (all P < 0.05). Tirofiban was found to be associated with superior clinical outcomes in anterior circulation stroke and major stroke patients [adjusted odds ratio (OR) = 2.163, 95% confidence interval (CI) = 1.130-4.140, P = 0.02 and adjusted OR = 2.361, 95% CI = 1.326-4.202, P = 0.004, respectively] and a lower risk of mortality at 90-day follow-ups (adjusted OR = 0.159, 95% CI = 0.042-0.599, P = 0.007 and adjusted OR = 0.252, 95% CI = 0.103-0.621, P = 0.003, respectively). There was no significant difference in sICH between the two groups. Conclusions: Tirofiban in AIS patients with LAA undergoing EVT is safe and may benefit the functional outcomes in anterior circulation and major stroke patients and showed a trend for reduced mortality.
Objective: To investigate the safety and efficacy of tirofiban in acute ischemic stroke (AIS) patients with large artery atherosclerosis (LAA) stroke etiology receiving endovascular therapy (EVT). Methods: In this multi-center prospective study, patients who were considered to have an indication received a low dose intra-arterial bolus (0.25-1 mg) of tirofiban. The safety and efficacy outcomes at 90-day follow-ups included symptomatic intracranial hemorrhage (sICH), recanalization rate, functional outcome, and mortality. Results: Among the 649 AISpatients with LAA, those in the tirofiban group (n = 244) showed higher systolic blood pressure (BP) and NIHSS score on admission, puncture-to-recanalization time, lower frequency of intravenous thrombolysis and intra-arterial thrombolysis, higher frequency of antiplatelet, heparinization, mechanical stent retrieval, aspiration, balloon angioplasty, and more retrieval times compared with those in the non-tirofiban group (n = 405) (all P < 0.05). Tirofiban was found to be associated with superior clinical outcomes in anterior circulationstroke and major strokepatients [adjusted odds ratio (OR) = 2.163, 95% confidence interval (CI) = 1.130-4.140, P = 0.02 and adjusted OR = 2.361, 95% CI = 1.326-4.202, P = 0.004, respectively] and a lower risk of mortality at 90-day follow-ups (adjusted OR = 0.159, 95% CI = 0.042-0.599, P = 0.007 and adjusted OR = 0.252, 95% CI = 0.103-0.621, P = 0.003, respectively). There was no significant difference in sICH between the two groups. Conclusions: Tirofiban in AISpatients with LAA undergoing EVT is safe and may benefit the functional outcomes in anterior circulation and major strokepatients and showed a trend for reduced mortality.
Authors: Jeffrey L Saver; Mayank Goyal; Alain Bonafe; Hans-Christoph Diener; Elad I Levy; Vitor M Pereira; Gregory W Albers; Christophe Cognard; David J Cohen; Werner Hacke; Olav Jansen; Tudor G Jovin; Heinrich P Mattle; Raul G Nogueira; Adnan H Siddiqui; Dileep R Yavagal; Blaise W Baxter; Thomas G Devlin; Demetrius K Lopes; Vivek K Reddy; Richard du Mesnil de Rochemont; Oliver C Singer; Reza Jahan Journal: N Engl J Med Date: 2015-04-17 Impact factor: 91.245
Authors: Lars Kellert; Christian Hametner; Stefan Rohde; Martin Bendszus; Werner Hacke; Peter Ringleb; Sibylle Stampfl Journal: Stroke Date: 2013-03-05 Impact factor: 7.914
Authors: Yan Zhang; Jianliang Wang; Zhaoxi Ma; Guihua Mu; Da Liang; Yifan Li; Xiaoyan Qian; Luyuan Zhang; Fang Shen; Lei Zhang; Jie Yu; Yang Liu Journal: Front Neurol Date: 2022-10-04 Impact factor: 4.086